A Aralex Aachen research explorer

Search

From

To

Institution

Field

Type

Open access only Cited by patents (Lens) Include non-Aachen papers (citing/cited)

Papers matching “lanifibranor” 5

Sort: Relevance Cited Newest Oldest Fwci Patents ⇩ CSV

Not finding it? Sign in to also search OpenAlex live.

Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention
2021 Annals of Translational Medicine article Medicine Liver Disease Diagnosis and Treatment Open access cited by 1 patent

Frank Tacke, Ralf Weiskirchen

154

citations
PPARs in molecular pathogenesis and drug treatment of type 2 diabetes-related MASLD
2025 Exploration of Digestive Diseases article Biochemistry, Genetics and Molecular Biology Peroxisome Proliferator-Activated Receptors Open access

Amedeo Lonardo, Ralf Weiskirchen

6

citations
Pharmacological chemoprevention of hepatocellular carcinoma: hype, hope, or reality?
2026 Hepatoma Research article Medicine Liver Disease Diagnosis and Treatment Open access

Ralf Weiskirchen, Amedeo Lonardo

0

citations
Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages☆
2020 Journal of Hepatology article Biochemistry, Genetics and Molecular Biology Peroxisome Proliferator-Activated Receptors Open access cited by 2 patents

Sander Lefere, Tobias Puengel, Jana Hundertmark, Christian Penners, Anna Katharina Frank, Adrien Guillot, +9 more

315

citations
Editorial: Reviews in gastrointestinal and hepatic pharmacology: 2024
2026 Frontiers in Pharmacology editorial Open access

Anna Maria Giudetti, Ralf Weiskirchen

0

citations

5 results